QX004N / Qyuns Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
QX004N / Qyuns Therap
ChiCTR2300075645: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QX004N Injection in Adults with Moderate to Severe Plaque Psoriasis

Not yet recruiting
2
160
 
Subcutaneous injection 100mg QX004N Injection (Week0, Week4, Week12, Week20, Week28); Subcutaneous injection 200mg QX004N Injection (Week36, Week44); Subcutaneous injection 200mg QX004N Injection (Week0, Week4, Week12, Week20, Week28); Subcutaneous injection 200mg QX004N Injection (Week36, Week44); Subcutaneous injection 200mg QX004N Injection (Week0, Week4, Week16, Week28); Subcutaneous injection 200mg QX004N Injection (Week36, Week44); Subcutaneous injection Placebo (Week0, Week4, Week12) / 200mg QX004N Injection (Week16, Week20, Week28, Week36, Week44)
Peking University People's Hospital; Qyuns Therapeutics Co., Ltd., Qyuns Therapeutics Co., Ltd.
Adult subjects with moderate to severe plaque psoriasis
 
 
ChiCTR2100051001: A phase I clinical study for pharmacokinetics, safety, tolerance and immunogenicity of QX004N in healthy volunteers: a single-center, randomized, double-blind, single-dose escalation, placebo-controlled study

Recruiting
1
45
 
QX004N Injection ;Placebo
The First Hospital of Jilin University; Jiangsu Qyuns Therapeutics Co., Ltd., self-funded
Adult subjects with moderate to severe plaque psoriasis
 
 
ChiCTR2200067007: A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, Intravenous Administration Study of QX004N for the Pharmacokinetics, Safety, Tolerability, and Immunogenicity in Healthy Subjects

Not yet recruiting
1
40
 
QX004N injection ;Placebo
Peking University Third Hospitol; Jiangsu Qyuns Therapeutics Co., Ltd., Qyuns therapeutics CO.,LTD.
Crohn's disease
 
 
ChiCTR2200067074: A Phase Ib, Multicenter, Randomized, Double-Blind, Multi-Dose Escalation, Placebo-Controlled Study Investigating the Safety, Tolerability, Efficacy, Pharmacokinetics and Immunogenicity of QX004N in the Subjects with Moderate to Severe Plaque-type Psoriasis

Not yet recruiting
1
30
 
150mg/ 300mg/ 600mg QX004N injection ;Placebo
The First Hospital of Jilin University; Jiangsu Qyuns Therapeutics Co., Ltd., Self-funded
Adult subjects with moderate to severe plaque psoriasis
 
 

Download Options